Shingrix logo

Product menu

Cancer patient looking far, wearing headscarf.

SHINGRIX is available now and is the first and only non-live vaccine for Shingles1,2

Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:

  • adults 50 years of age or older;
  • adults 18 years of age or older at increased risk of HZ.

The use of Shingrix should be in accordance with official recommendations.

SHINGLES IN IMMUNOCOMPROMISED (IC) PATIENTS

Following primary Varicella-zoster virus (VZV) infection, VZV lies dormant in the sensory dorsal root ganglia. Reactivation of the latent virus leads to the clinical manifestations of shingles and is associated with immune senescence or suppression of the immune system.3

  • Immunocompromised (IC) patients are at increased risk of shingles and its complications compared to the general population.4
  • In IC patients, rash may be severe and long lasting.5
  • In IC individuals, the rash may affect multiple dermatomes.5
  • Disseminated disease is more likely to occur in those who are severely immunocompromised, with a case fatality rate reported to be between 5-15%.5
  • IC patients are more likely to develop recurrent HZ.4
Patient's Shingles Rash

From Dworkin RH et al., Clinical Infectious Diseases, 2007

Hear more from an expert on why the risk of Shingles increases with ageing and immunocompromise.

WATCH THE SHORT VIDEO

Immunocompromised (IC) patients are at increased risk of shingles and its complications compared to the general population.4

Incidence rate of HZ in various Immunocompromised (IC) populations in England 2000-2012 (data from a retrospective cohort study using CPRD) in Adults ≥18 years of age4

Graph to show the incidence of HZ is higher in immunocompromised patients

n = Number of individuals
†The graph has been independently created by GSK from the original data.
Incidence rates of HZ in IC populations in England [data from a retrospective cohort study using the Clinical Practice Research Datalink (CPRD) in adults ≥18 years of age (2000-2012)].4

Learn more about SHINGRIX

Red icon, two syringes pointing in opposite directions

Ready to vaccinate with SHINGRIX?

Familiarise yourself with the dosing and administration of SHINGRIX.1,2

Dosing and administration Info

Red patients icon, showing 3 patient figures

Who is at risk of shingles?

There is a 1 in 4 lifetime risk of developing shingles in the general population.3 Decline in VZV-specific cellular immunity due to age or immunocompromise increases the risk of shingles.6,7

VIEW PATIENT PROFILES

Red circular icon

Learn more about the efficacy and safety profile of SHINGRIX in IC patients

SHINGRIX has been investigated in a range of immunocompromised (IC) patient populations, including solid tumours, haematologic malignancies, renal transplants and autologous haematopoietic stem cell transplants (auHSCT).8-11

IC EFFICACY AND SAFETY DATA

References

  1. Shingrix, GB Summary of Product Characteristics (SPC).
  2. Shingrix, Northern Ireland Summary of Product Characteristics (SPC)
  3. DH Green Book ch 28a - Shingles. August 2021.
  4. Yanni EA, Ferreira G, Guennec M, et al; BMJ Open 2018;8:e020528
  5. UK NICE Clinical Knowledge Summaries, Shingles. Accessed September 2022;
  6. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009 137 38-472.
  7. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13):1338-43.
  8. Bastides A, de la Serna J, El Idrissi M, et al.; for the ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial [suppl]. JAMA. 2019 July;322(2):123-133.
  9. Dagnew AF, Ilhan O, Lee WS, et al.; on behalf of the Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 September;19(9):988-1000.
  10. Vink P, Torelle JMR, Sanchez Fructuoso A, et al.; for the Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020 January;70(2):181-190.
  11. Vink P, Mignorance ID, Alonso CM, et al.; on behalf of the Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019 April;125(8):1301-1312.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

November 2022 | PM-GB-SGX-WCNT-220006 (V1.0)